Rectal cancer treatment depends on how far the tumour has grown, where it sits in the rectum, and what the pelvic MRI and biopsy show. Selected early cancers can be removed locally or treated with surgery first. For many locally advanced cancers, chemotherapy and radiation are given before surgery. Some patients can consider avoiding immediate surgery if the tumour is no longer detectable after treatment and they can commit to close follow-up. [1–3]
By Dr Raman Narang, Consultant Medical & Hemato-Oncologist, New Delhi
One of the first questions patients ask is, “If the cancer can be removed, why am I being advised to start with chemotherapy or radiation?” In rectal cancer, treatment before surgery can improve the chance of removing the tumour with clear margins and, in selected cases, create an opportunity to preserve the rectum. If you are seeking rectal cancer treatment in Delhi, ask your team to explain which findings on the pelvic MRI are driving the recommendation. This page focuses on rectal adenocarcinoma, the most common type. Rectal neuroendocrine tumours and anal cancer follow different treatment pathways. [1, 2]
1. What are the symptoms of rectal cancer?
Symptoms can include blood in the stool, a persistent change in bowel habits, or a feeling that you still need to pass stool after opening your bowels. Some people have rectal discomfort, unexplained weight loss, or fatigue from iron-deficiency anaemia. Persistent or recurrent rectal bleeding deserves assessment, including in someone who has previously been diagnosed with piles. [2, 3]
A personal history of certain colorectal polyps, long-standing inflammatory bowel disease, a family history of colorectal cancer, and inherited conditions such as Lynch syndrome can increase risk. Rectal cancer can also occur in younger adults and in people without a family history. [2, 3]
Heavy bleeding, fainting, or severe abdominal pain with vomiting and an inability to pass stool or gas needs urgent medical assessment. [3]
2. How is rectal cancer diagnosed and staged?
A colonoscopy with biopsy usually confirms the diagnosis. The examination helps locate the tumour and, when the scope can pass safely, allows the doctor to check the rest of the colon. A contrast CT of the chest, abdomen, and pelvis looks for spread to distant organs. A baseline blood test called CEA can help with later monitoring. [1–3]
A pelvic MRI with a dedicated rectal cancer protocol answers questions that can change treatment:
- How low is the tumour, and how close is it to the muscles that control bowel movements?
- How far has it grown through the rectal wall, and are nearby lymph nodes involved?
- Is it close to the mesorectal fascia, the boundary surgeons use to assess the likelihood of a clear margin?
- Does the scan show tumour in veins outside the rectal wall, called extramural venous invasion (EMVI)? [1, 2]
The biopsy should also be tested for mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-high). For locally advanced rectal cancer, this result should ideally be available before treatment starts because it can change the first recommendation. It may also prompt evaluation for Lynch syndrome. [1, 2]
3. When can early rectal cancer be treated with surgery first?
A small, low-risk T1 rectal cancer may be suitable for local removal through the anus. The removed tissue is examined to check tumour depth, margins, and whether cancer cells have entered small blood vessels or lymphatic channels. If the pathology shows higher-risk features, a larger operation may be advised because local excision does not remove the regional lymph nodes. [2, 3]
For many other early tumours, surgery removes the affected segment of rectum and the surrounding tissue containing regional lymph nodes. Total mesorectal excision (TME) is a standard surgical approach for many mid and low rectal cancers. Whether the bowel can be reconnected depends on the tumour’s location, its relationship to the sphincter muscles, and the likelihood of achieving clear margins. Some patients need a temporary stoma to protect the bowel join. Others may need a permanent colostomy. [2, 3]
4. When are chemotherapy or radiation given before surgery?
For many patients with locally advanced rectal cancer, the first treatment is chemotherapy, radiation, or both. Total neoadjuvant therapy (TNT) means giving the planned chemotherapy and pelvic radiation before surgery. It is commonly offered for low rectal tumours or when MRI shows higher-risk features, such as a threatened surgical margin or growth into nearby structures. [1, 2]
| Clinical situation | What the team usually discusses |
|---|---|
| Low rectal tumour or higher-risk MRI features | TNT, including the order of chemotherapy and radiation and how the response will be assessed. |
| Selected lower-risk, resectable disease | Whether chemotherapy with selective use of radiation, another preoperative approach, or surgery first is appropriate. Tumour height and MRI findings are central to this decision. |
| Locally advanced dMMR or MSI-high rectal cancer | Whether immunotherapy should be the first treatment. Dostarlimab is one option studied in this setting. Suitability, access, and the applicable Indian prescribing indication should be checked. [1, 2, 4] |
Chemotherapy treats disease throughout the body. Pelvic radiation treats the tumour and selected nearby areas. When radiation is given with a chemotherapy drug such as capecitabine to enhance its effect, the treatment is called chemoradiation. The team chooses the sequence based on the MRI, the goals of treatment, and the patient’s fitness and preferences. [1, 2]
Can a complete response allow me to avoid surgery?
A clinical complete response means the team finds no detectable residual tumour on reassessment with rectal examination, endoscopy, and pelvic MRI. Selected patients can consider watch and wait, a structured programme of frequent reassessment. A complete response is assessed across these tests, and local regrowth can still occur. Close follow-up helps the team detect it and assess whether surgery is needed. [1, 2, 5]
5. How is metastatic rectal cancer treated?
When rectal cancer has spread to the liver, lungs, abdominal lining, or another distant site, the team first asks whether all known sites could be removed or treated locally. Some patients with limited liver or lung metastases may still be treated with the aim of cure. The order of pelvic treatment, systemic therapy, and treatment to the metastases is decided together. [3, 6]
When all sites cannot be treated locally, systemic therapy is usually the main treatment. MMR/MSI, KRAS, NRAS, and BRAF results can guide the choice of immunotherapy or targeted treatment. For example, MSI-high or dMMR disease can make immunotherapy a first-line option. In selected patients with a RAS wild-type rectal cancer, an EGFR-targeted drug may be considered with chemotherapy. If the rectal tumour is causing troublesome bleeding, pain, or blockage, pelvic radiation or a procedure may also be needed for symptom relief. [3, 6]
What I look for clinically before recommending treatment
I review the original pelvic MRI with the biopsy report. I want to know how close the tumour is to the sphincter muscles, whether the surgeon is likely to achieve a clear margin, and whether the MMR result could change the first treatment. I also ask what matters most to the patient about bowel function and the possibility of a stoma. If organ preservation is a priority, I explain how we would assess the response and what follow-up would involve before deciding whether watch and wait is feasible.
How the next step is decided
| If the reports show… | The next discussion is about… |
|---|---|
| A small, low-risk T1 tumour | Whether local excision is sufficient and which pathology findings could change the plan |
| A low rectal tumour or a threatened surgical margin | Treatment before surgery and whether sphincter preservation is feasible |
| Locally advanced dMMR or MSI-high disease | Immunotherapy first and how response will be assessed |
| A clinical complete response after treatment | Watch and wait versus surgery, including the follow-up commitment |
| Limited liver or lung metastases | Whether all sites can be treated and in what sequence |
What to bring to a rectal cancer consultation in Delhi
- Colonoscopy report, including the tumour’s location and any endoscopy images.
- Biopsy report and details for obtaining the slides or tissue block.
- Pelvic MRI and staging CT reports with the original images.
- CEA and MMR/MSI results, plus any molecular profiling already completed.
- Records of previous surgery, chemotherapy, or pelvic radiation, if applicable.
- A note of current bleeding, bowel symptoms, weight changes, and questions about bowel function or a stoma.
Frequently asked questions
Does every patient with rectal cancer need radiation?
Radiation is important for many locally advanced tumours. Some early cancers and selected lower-risk tumours can be treated without it. The pelvic MRI, tumour height, and planned operation help guide the decision. [1, 2]
Does a low rectal tumour always mean a permanent stoma?
The chance of a permanent stoma depends on whether the tumour involves the sphincter muscles, whether clear margins can be achieved, and what bowel function is likely after reconstruction. Ask the surgeon to explain both the expected operation and what might change it. [2, 3]
If the tumour disappears after treatment, can I skip surgery?
A confirmed clinical complete response can make watch and wait an option. The decision should include a written surveillance plan and a discussion about what happens if the tumour regrows. [1, 2, 5]
Does a positive regional lymph node mean stage IV rectal cancer?
Regional lymph node involvement usually means stage III if there is no distant spread. Stage III rectal cancer is commonly treated with the aim of cure. [2, 3]
Before treatment starts, ask your team to identify the MRI finding that matters most, whether the MMR result changes the plan, and when the response will be reassessed. If preserving the rectum is important to you, discuss it early so the team can explain what is realistic and what follow-up would require.
This page is for general education. Individual treatment decisions require review of your pathology, imaging, symptoms, and overall health by your treating team.
Clinical references
- American Society of Clinical Oncology. Management of Locally Advanced Rectal Cancer: ASCO Guideline. 2024.
- European Society for Medical Oncology. Localised Rectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. 2025.
- National Comprehensive Cancer Network. NCCN Guidelines for Patients: Rectal Cancer. 2026.
- Cercek A and colleagues. Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine, 2025.
- Garcia-Aguilar J and colleagues. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. OPRA trial, Journal of Clinical Oncology, 2022.
- American Society of Clinical Oncology. Treatment of Metastatic Colorectal Cancer: ASCO Guideline.